Duhao Net

Duhao Net helps individual entrepreneurs and enterprises find high-quality suppliers, reduce procurement costs, and make transactions easier.

Zhejiang Anglikang Pharmaceutical Co., Ltd.: A pharmaceutical API and drug preparation factory

Release time：2025-06-27 18:57:38 Source：DuHao

Contact Us Today

Tel : +86 0575-83123228

Email: net.fei@163.com

Address: No. 1000, Shengzhou Avenue North, Shengzhou City, Zhejiang Province, China.

Zhejiang Anglikang Pharmaceutical Co., Ltd. is a modern pharmaceutical enterprise specializing in the R&D, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Established in December 2001 and headquartered in Shengzhou, Zhejiang, the company has grown into a leading player in China's pharmaceutical industry, ranking among the Top 100 Pharmaceutical Enterprises in China. It was listed on the Shenzhen Stock Exchange in October 2018.

With major production bases in Zhejiang, Jiangsu, Fujian, and Jiangxi, and over 10 holding subsidiaries, Anglikang has built a full industry chain spanning intermediates, APIs, and formulations. The company focuses on cardiovascular drugs, oral cephalosporins, nephrology treatments, and anesthetic analgesics, with a strong presence in both domestic and international markets.

Core Business & Market Leadership

Anglikang’s revenue structure comprises:

  • APIs (48.60%) – Leading global supplier of oral cephalosporin APIs (e.g., cefaclor, cefradine).

  • Formulations (35.57%) – Key products include Cefaclor Sustained-Release Tablets (Shuaixian), the first in China to pass generic drug consistency evaluation, and levamlodipine besylate tablets, a top-selling antihypertensive drug.

  • Specialty Intermediates (13.01%) – High-value intermediates for global markets.

Competitive Advantages:

  • World’s largest α-keto acid API producer, partnering with Fresenius AG (Fortune 500).

  • Pioneer in consistency evaluation for generics, ensuring quality parity with originator drugs.

  • Vertically integrated cost-efficient supply chain, supporting global exports to 30+ countries (FDA, EDQM certified).

Innovation & R&D Strength

Anglikang drives growth through "dual-wheel" strategy: scientific innovation + industrial chain integration. Key highlights:

  • R&D Investment: Over ¥100 million annually (5%+ of revenue), with 23 authorized patents and 8 national drug standards.

  • Platforms:

    • Provincial Key Enterprise Research Institute, postdoctoral workstation, and academician expert workstation.

    • Collaboration with Zhejiang University, China Pharmaceutical University, and global R&D teams.

  • Pipeline: 20+ projects in high-end generics, improved new drugs, and innovative therapies (e.g., drug-resistant infections, metabolic diseases).

Global Market & Strategy

  • Domestic: Products included in China's Medical Insurance Procurement, with partnerships like Sinopharm and CR Pharma.

  • International: APIs exported to Europe, Americas, and Southeast Asia; expanding formulations in emerging markets.

  • Future Focus:

    • Green manufacturing and high-barrier specialty APIs.

    • Overseas partnerships/M&A to accelerate global footprint.

Mission & Vision

  • Mission: "Produce safe medicine that everyone can afford."

  • Vision: Become a top 100 global innovator with comprehensive competitiveness.

ESG Commitment

  • Environmental: Advanced wastewater/gas treatment systems.

  • Social: Medicine donations, health poverty alleviation, and employee development programs.

  • Governance: Compliance-first culture with GMP/ISO-certified quality systems.

DuHao Net